Amazon foregrounds consumer AI with its new health-improvement wearable

Trotting out a new digital health assistant this week, Amazon is emphasizing the wearable’s incorporation of AI to guide users toward some complicated goals.

These include reducing body mass index (BMI) and experiencing less stress by speaking more positively.

To the world, the device will look like a watchband minus the watch. That’s because the hardware faces the wearer’s wrist.

The band’s sleek circular appearance when it’s not being worn may explain why the Big Tech megaretailer is calling the product—a combo of app, sensor panel and wristband—the Halo.

In fact, the name refers to two parts. Halo itself is a mobile app while Halo Band is what you wear.

As for the sophisticated uses of AI, the Halo supplies users with feedback and guidance across five named health indices. The idea behind “Activity” and “Sleep” are self-explanatory.

But, as explained in Amazon blog posts, “Body” uses AI to image and track BMI by taking full-body photos on a smartphone, while “Tone” taps AI to give feedback on tone of voice.

The other section, “Labs,” designs and measures performance on workouts, challenges and the like.

In an Amazon press release, the product receives an endorsement from Eduardo Sanchez, MD, MPH, chief medical officer for prevention at the American Heart Association, which shared data with Amazon during Halo product development.

“Through our Center for Health Technology and Innovation, we [at the AHA] are pleased to provide our evidence-based science as part of this solution, which we believe has the potential to drive behavior change towards healthier lives,” Sanchez says.

Amazon is selling the package at an “early access” price of $64.99.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.